Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SSR181507
- Development stage
- Preclinical
- Lead developer
- Sanofi
- Modality
- Small Molecules
- Administration
- Intraperitoneal (i.p.)
01
Overview
SSR181507 is a dopamine D₂ receptor antagonist/partial agonist and a serotonin 5-HT₁A receptor agonist. It is a novel tropanemethanamine benzodioxane derivative with high affinities for D₂-like and 5-HT₁A receptors. Initially developed by **Sanofi-Aventis**, SSR181507 has shown potential in treating schizophrenia and exhibits mixed antidepressant and anxiolytic activities in animal models.
- Other names
- 8-Azabicyclo(3.2.1)octane-3-methanamine, 8-benzoyl-N-(((2S)-7-chloro-2,3-dihydro-1,4-benzodioxin-2-yl)methyl)-, (3-exo)-H276H25KW0H-276H25KW0H 276H25KW0UNII-H276H25KW0UNII-H-276H25KW0UNII-H 276H25KW0737743-26-9
02
Targets
DRD2 (Dopamine D2 Receptor)DRD3 (Dopamine receptor D3)HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))HTR2A (Serotonin receptor 5-HT2A)
Beyond the preview
Go deeper on SSR181507.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SSR181507.